360 related articles for article (PubMed ID: 8344262)
1. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation.
Verdin E; Paras P; Van Lint C
EMBO J; 1993 Aug; 12(8):3249-59. PubMed ID: 8344262
[TBL] [Abstract][Full Text] [Related]
2. Closed chromatin architecture is induced by an RNA duplex targeting the HIV-1 promoter region.
Suzuki K; Juelich T; Lim H; Ishida T; Watanebe T; Cooper DA; Rao S; Kelleher AD
J Biol Chem; 2008 Aug; 283(34):23353-63. PubMed ID: 18519571
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation.
Van Lint C; Emiliani S; Ott M; Verdin E
EMBO J; 1996 Mar; 15(5):1112-20. PubMed ID: 8605881
[TBL] [Abstract][Full Text] [Related]
4. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.
Chun TW; Carruth L; Finzi D; Shen X; DiGiuseppe JA; Taylor H; Hermankova M; Chadwick K; Margolick J; Quinn TC; Kuo YH; Brookmeyer R; Zeiger MA; Barditch-Crovo P; Siliciano RF
Nature; 1997 May; 387(6629):183-8. PubMed ID: 9144289
[TBL] [Abstract][Full Text] [Related]
5. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.
Finzi D; Hermankova M; Pierson T; Carruth LM; Buck C; Chaisson RE; Quinn TC; Chadwick K; Margolick J; Brookmeyer R; Gallant J; Markowitz M; Ho DD; Richman DD; Siliciano RF
Science; 1997 Nov; 278(5341):1295-300. PubMed ID: 9360927
[TBL] [Abstract][Full Text] [Related]
6. The cell biology of HIV-1 latency and rebound.
Mbonye U; Karn J
Retrovirology; 2024 Apr; 21(1):6. PubMed ID: 38580979
[TBL] [Abstract][Full Text] [Related]
7. The Dual Roles of Activating Transcription Factor 3 (ATF3) in Inflammation, Apoptosis, Ferroptosis, and Pathogen Infection Responses.
Liu S; Li Z; Lan S; Hao H; Baz AA; Yan X; Gao P; Chen S; Chu Y
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255898
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing.
Lyons DE; Kumar P; Roan NR; Defechereux PA; Feschotte C; Lange UC; Murthy N; Sameshima P; Verdin E; Ake JA; Parsons MS; Nath A; Gianella S; Smith DM; Kallas EG; Villa TJ; Strange R; Mwesigwa B; Furler O'Brien RL; Nixon DF; Ndhlovu LC; Valente ST; Ott M
Viruses; 2023 Oct; 15(11):. PubMed ID: 38005849
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 Gag co-localizes with euchromatin histone marks at the nuclear periphery.
Chang J; Parent LJ
J Virol; 2023 Dec; 97(12):e0117923. PubMed ID: 37991367
[TBL] [Abstract][Full Text] [Related]
10. Mathematical Models of HIV-1 Dynamics, Transcription, and Latency.
D'Orso I; Forst CV
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896896
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional Stochasticity as a Key Aspect of HIV-1 Latency.
Damour A; Slaninova V; Radulescu O; Bertrand E; Basyuk E
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766375
[TBL] [Abstract][Full Text] [Related]
12. New Concepts in Therapeutic Manipulation of HIV-1 Transcription and Latency: Latency Reversal versus Latency Prevention.
Lewis CA; Margolis DM; Browne EP
Viruses; 2023 Jul; 15(8):. PubMed ID: 37632019
[TBL] [Abstract][Full Text] [Related]
13. Genetic variation of the HIV-1 subtype C transmitted/founder viruses long terminal repeat elements and the impact on transcription activation potential and clinical disease outcomes.
Madlala P; Mkhize Z; Naicker S; Khathi SP; Maikoo S; Gopee K; Dong KL; Ndung'u T
PLoS Pathog; 2023 Jun; 19(6):e1011194. PubMed ID: 37307292
[TBL] [Abstract][Full Text] [Related]
14. Loss of In Vivo Replication Fitness of HIV-1 Variants Resistant to the Tat Inhibitor, dCA.
Ling L; Leda AR; Begum N; Spagnuolo RA; Wahl A; Garcia JV; Valente ST
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112931
[TBL] [Abstract][Full Text] [Related]
15. Insertion Depth Modulates Protein Kinase C-δ-C1b Domain Interactions with Membrane Cholesterol as Revealed by MD Simulations.
Judge PT; Overall SA; Barnes AB
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902029
[TBL] [Abstract][Full Text] [Related]
16. The lysine methyltransferase SMYD5 amplifies HIV-1 transcription and is post-transcriptionally upregulated by Tat and USP11.
Boehm D; Lam V; Schnolzer M; Ott M
Cell Rep; 2023 Mar; 42(3):112234. PubMed ID: 36897778
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic Regulation of HIV-1 Sense and Antisense Transcription in Response to Latency-Reversing Agents.
Li R; Caico I; Xu Z; Iqbal MS; Romerio F
Noncoding RNA; 2023 Jan; 9(1):. PubMed ID: 36649034
[TBL] [Abstract][Full Text] [Related]
18. Activation of HIV-1 proviruses increases downstream chromatin accessibility.
Shah R; Gallardo CM; Jung YH; Clock B; Dixon JR; McFadden WM; Majumder K; Pintel DJ; Corces VG; Torbett BE; Tedbury PR; Sarafianos SG
iScience; 2022 Dec; 25(12):105490. PubMed ID: 36505924
[TBL] [Abstract][Full Text] [Related]
19. FBXO34 promotes latent HIV-1 activation by post-transcriptional modulation.
Yang X; Zhao X; Zhu Y; Xun J; Wen Q; Pan H; Yang J; Wang J; Liang Z; Shen X; Liang Y; Lin Q; Liang H; Li M; Chen J; Jiang S; Xu J; Lu H; Zhu H
Emerg Microbes Infect; 2022 Dec; 11(1):2785-2799. PubMed ID: 36285453
[No Abstract] [Full Text] [Related]
20. Genome-wide CRISPR screens identify combinations of candidate latency reversing agents for targeting the latent HIV-1 reservoir.
Dai W; Wu F; McMyn N; Song B; Walker-Sperling VE; Varriale J; Zhang H; Barouch DH; Siliciano JD; Li W; Siliciano RF
Sci Transl Med; 2022 Oct; 14(667):eabh3351. PubMed ID: 36260688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
